Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Hajime, Aino"'
Autor:
Shigeo Shimose, Atsushi Hiraoka, Masatoshi Tanaka, Hideki Iwamoto, Takaaki Tanaka, Kazunori Noguchi, Hajime Aino, Taizo Yamaguchi, Satoshi Itano, Hideya Suga, Takashi Niizeki, Etsuko Moriyama, Tomotake Shirono, Yu Noda, Naoki Kamachi, Shusuke Okamura, Masahito Nakano, Takumi Kawaguchi, Ryoko Kuromatsu, Hironori Koga, Takuji Torimura
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract This study aimed to investigate the clinical characteristics of patients with unresectable hepatocellular carcinoma (HCC), who were eligible for sequential systemic therapy. We evaluated 365 patients with HCC who underwent systemic therapy a
Externí odkaz:
https://doaj.org/article/a8c7a028541d4aafa780bbde3d8cc0b9
Autor:
Shigeo Shimose, Atsushi Hiraoka, Masahito Nakano, Hideki Iwamoto, Masatoshi Tanaka, Takaaki Tanaka, Kazunori Noguchi, Hajime Aino, Kei Ogata, Masahiko Kajiwara, Satoshi Itano, Yoshinori Yokokura, Taizo Yamaguchi, Hiroshi Kawano, Norito Matsukuma, Hideya Suga, Takashi Niizeki, Tomotake Shirono, Yu Noda, Naoki Kamachi, Shusuke Okamura, Takumi Kawaguchi, Hironori Koga, Takuji Torimura
Publikováno v:
Cancer Medicine, Vol 10, Iss 23, Pp 8530-8541 (2021)
Abstract Background and Aims Sequential therapy with molecular‐targeted agents (MTAs) is considered effective for unresectable hepatocellular carcinoma (HCC) patients. This study purposed to evaluate the efficacy of sequential therapy with sorafeni
Externí odkaz:
https://doaj.org/article/0894e9642c0c4631b38c4aa5d3985b9c
Autor:
Masatoshi Kudo, Kazuomi Ueshima, Masafumi Ikeda, Takuji Torimura, Nobukazu Tanabe, Hiroshi Aikata, Namiki Izumi, Takahiro Yamasaki, Shunsuke Nojiri, Keisuke Hino, Hidetaka Tsumura, Teiji Kuzuya, Norio Isoda, Michihisa Moriguchi, Hajime Aino, Akio Ido, Naoto Kawabe, Kazuhiko Nakao, Yoshiyuki Wada, Sadahisa Ogasawara, Kenichi Yoshimura, Takuji Okusaka, Junji Furuse, Norihiro Kokudo, Kiwamu Okita, Philip James Johnson, Yasuaki Arai
Publikováno v:
Liver Cancer (2022)
Introduction Several clinical trials comparing the efficacy and safety of transarterial chemoembolisation (TACE) plus molecular-targeted agents versus TACE alone revealed no clinical benefits in progression-free survival (PFS) or overall survival (OS
Externí odkaz:
https://doaj.org/article/cc83eaff16bc4510925c92f9ce0993dd
Autor:
Toshihiro Kawaguchi, Yuya Araki, Akira Kajiwara, Koji Nakao, Shigenari Sakakibara, Yu Sasaki, Hajime Aino, Ryuichiro Maekawa, Yoshinobu Okabe, Takumi Kawaguchi
Publikováno v:
Internal Medicine; 2024, Vol. 63 Issue 12, p1713-1718, 6p
Autor:
Masahiko Kajiwara, Hironori Koga, Takumi Kawaguchi, Taizo Yamaguchi, Hideya Suga, Yu Noda, Shusuke Okamura, Masatoshi Tanaka, Atsushi Hiraoka, Takaaki Tanaka, Takuji Torimura, Tomotake Shirono, Naoki Kamachi, Hiroshi Kawano, Masahito Nakano, Takashi Niizeki, Satoshi Itano, Shigeo Shimose, Kazunori Noguchi, Yoshinori Yokokura, Hajime Aino, Kei Ogata, Hideki Iwamoto, Norito Matsukuma
Publikováno v:
Cancer Medicine, Vol 10, Iss 23, Pp 8530-8541 (2021)
Cancer Medicine
Cancer Medicine
Background and Aims Sequential therapy with molecular‐targeted agents (MTAs) is considered effective for unresectable hepatocellular carcinoma (HCC) patients. This study purposed to evaluate the efficacy of sequential therapy with sorafenib (SORA)
Autor:
Masatoshi, Kudo, Kazuomi, Ueshima, Masafumi, Ikeda, Takuji, Torimura, Nobukazu, Tanabe, Hiroshi, Aikata, Namiki, Izumi, Takahiro, Yamasaki, Shunsuke, Nojiri, Keisuke, Hino, Hidetaka, Tsumura, Teiji, Kuzuya, Norio, Isoda, Kohichiroh, Yasui, Hajime, Aino, Akio, Ido, Naoto, Kawabe, Kazuhiko, Nakao, Yoshiyuki, Wada, Osamu, Yokosuka, Kenichi, Yoshimura, Takuji, Okusaka, Junji, Furuse, Norihiro, Kokudo, Kiwamu, Okita, Philip James, Johnson, Yasuaki, Arai, Manabu, Morimoto
Publikováno v:
Gut
Ann Transl Med
Ann Transl Med
ObjectiveThis trial compared the efficacy and safety of transarterial chemoembolisation (TACE) plus sorafenib with TACE alone using a newly established TACE-specific endpoint and pre-treatment of sorafenib before initial TACE.DesignPatients with unre
Autor:
Hideki, Iwamoto, Takashi, Niizeki, Hiroaki, Nagamatsu, Kazuomi, Ueshima, Takako, Nomura, Teiji, Kuzuya, Kazuhiro, Kasai, Yohei, Kooka, Atsushi, Hiraoka, Rie, Sugimoto, Takehiro, Yonezawa, Akio, Ishihara, Akihiro, Deguchi, Hirotaka, Arai, Shigeo, Shimose, Tomotake, Shirono, Masahito, Nakano, Shusuke, Okamura, Yu, Noda, Naoki, Kamachi, Miwa, Sakai, Hiroyuki, Suzuki, Hajime, Aino, Norito, Matsukuma, Satoru, Matsugaki, Kei, Ogata, Yoichi, Yano, Takato, Ueno, Masahiko, Kajiwara, Satoshi, Itano, Kunitaka, Fukuizumi, Hiroshi, Kawano, Kazunori, Noguchi, Masatoshi, Tanaka, Taizo, Yamaguchi, Ryoko, Kuromatsu, Atsushi, Kawaguchi, Hironori, Koga, Takuji, Torimura, New Fp Study Group, Kurume Liver Cancer Study Group Of Japan
Publikováno v:
Cancers
Cancers, Vol 13, Iss 646, p 646 (2021)
Volume 13
Issue 4
Cancers, Vol 13, Iss 646, p 646 (2021)
Volume 13
Issue 4
BACKROUND: Not all patients with hepatocellular carcinoma (HCC) benefit from treatment with molecular targeted agents such as sorafenib. We investigated whether New-FP (fine-powder cisplatin and 5-fluorouracil), a hepatic arterial infusion chemothera
Autor:
HAJIME AINO1 aino0217@kph.biglobe.ne.jp, SHUJI SUMIE1, TAKASHI NIIZEKI1, RYOKO KUROMATSU1, NOBUYOSHI TAJIRI1, MASAHITO NAKANO1, MANABU SATANI1, SHUSUKE OKAMURA1, SHIGEO SHIMOSE1, KENSUKE MIYAHARA1, TAKUJI TORIMURA1
Publikováno v:
Molecular & Clinical Oncology. Jul2016, Vol. 5 Issue 1, p83-88. 6p.
Autor:
Hiroshi Aikata, Norio Isoda, Takuji Torimura, Junji Furuse, Kohichiroh Yasui, Keisuke Hino, Naoto Kawabe, Hajime Aino, Takuji Okusaka, Yoshiyuki Wada, Kenichi Yoshimura, Masafumi Ikeda, Kazuhiko Nakao, Teiji Kuzuya, Masatoshi Kudo, Yasuaki Arai, Takahiro Yamasaki, Kazuomi Ueshima, Namiki Izumi, Akio Ido
Publikováno v:
Journal of Clinical Oncology. 39:270-270
270 Background: To date many trials have been conducted to compare the efficacy and toxicity between TACE plus molecular targeted agents and TACE alone; all of them failed to show its clinical benefit in terms of progression free survival (PFS) or OS
Autor:
Hideki Iwamoto, Nobuyoshi Tajiri, Ryoko Kuromatsu, Osamu Nakashima, Manabu Satani, Takuji Torimura, Tatsuyuki Tonan, Hajime Aino, Tomotake Shirono, Shigeo Shimose, Koji Okuda, Masahito Nakano, Takashi Niizeki, Shusuke Okamura, Shuji Sumie
Publikováno v:
Digestive and Liver Disease. 48:945-952
Background Poor differentiation and microvascular invasion are indicators of poor outcome after hepatectomy for patients with small hepatocellular carcinoma (HCC). Aims We investigated whether gadoxetic acid-enhanced and diffusion-weighted magnetic r